Skip to main content
. 2021 Apr 6;12:2078. doi: 10.1038/s41467-021-22265-2

Fig. 3. MRI-based subtypes and disability progression in the placebo arms.

Fig. 3

The lesion-led subtype had a faster EDSS progression than the other two MS subtypes in both the training (a) and validation (b) sets. Only placebo arms (or comparator arms) of the clinical trials are included. In both a and b we used the log-rank test, with two-sided p-value, to compare survival curves (no correction for multiple comparisons). EDSS expanded disability status scale.